Critical analysis of treatment trials of rhesus macaques infected with Borrelia burgdorferi reveals important flaws in experimental design

Vector-Borne and Zoonotic Diseases

Volumn 12, Issue 7, 2012, Pages 535-538

  Wormser, Gary P ^a   Baker, Phillip J ^b   O'Connell, Susan ^c   Pachner, Andrew R ^d   Schwartz, Ira ^a   Shapiro, Eugene D ^e  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b American Lyme Disease Foundation   (United States)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e YALE UNIVERSITY   (United States)

Author keywords

Antibiotic therapy; C6 antibody; Ceftriaxone; Doxycycline; Erythema migrans; Lyme disease; Non human primates Post treatment Lyme disease syndrome

Indexed keywords

CEFTIOFUR; CEFTRIAXONE; DOXYCYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; BORRELIA BURGDORFERI; CLINICAL RESEARCH; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; EXPERIMENTAL DESIGN; EXPERIMENTAL MONKEY; HOST; HUMAN; LYME DISEASE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHESUS MONKEY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; BORRELIA BURGDORFERI; CEFTRIAXONE; DISEASE MODELS, ANIMAL; DOXYCYCLINE; LYME DISEASE; MACACA MULATTA; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

ANIMALIA; BORRELIA BURGDORFERI; MACACA MULATTA; PRIMATES;

EID: 84864041380     PISSN: 15303667     EISSN: 15577759     Source Type: Journal    
DOI: 10.1089/vbz.2012.1012     Document Type: Review

References (22)

1. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics- pharmacodynamics of antimicrobial therapy: It's not just for mice anymore. Clin Infect Dis 2007; 44:79-86.
2. Barer MR, Harwood CR. Bacterial viability and culturability. Adv Microbial Physiol 1999; 41:94-137.
3. Birch L, Dawson CE, Keer JT. A comparison of nucleic acid amplification techniques for the assessment of bacterial viability. Lett Appl Microbiol 2001; 33:296-301.
4. Bogosian G, Bourneuf Ev. A matter of bacterial life and death. EMBO Reports 2001; 2:770-774.
5. Embers ME, Barthold SW, Borda JT, et al. Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. PLoS One 2012; 7(1):e29914; doi:10.1371/Journal.pone.0029914.
6. Fallon BA, Keilp JG, Corbera KM, et al. A randomized, placebocontrolled trial of repeated Iv antibiotic therapy for Lyme encephalopathy. Neurology 2008; 70:992-1003.
7. Kelly DJ, Chulay JD, Mikesell P, et al. Serum concentration of penicillin, doxycycline, and ciprofloxacin during prolonged therapy in rhesus monkeys. J Infect Dis 1992; 166: 1184-1187.
8. Klempner MS. Controlled trials of antibiotic treatment in patients with post-Treatment chronic Lyme disease. vector Borne Zoonotic Dis 2002; 2:255-263.
9. Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345:85-92.
10. Li X, McHugh G, Damle N, et al. Burden and viability of Borrelia burgdorferi in skin or joints of patients with erythema migrans or Lyme arthritis. Arthritis Rheum 2011; 63:2238-2247.
11. Matsui H, Kumiya M, Ikeda C, et al. Comparative pharmacokinetics of YM-13115, ceftriaxone, and ceftazidime in rats, dogs, and rhesus monkeys. Antimicrob Agents Chemother 1984; 26:204-207.
12. Nowakowski J, Nadelman RB, Sell R, et al. Long-Term follow-Up of patients with culture-Confirmed Lyme disease. Am J Med 2003; 115:911-916.
13. Pachner AR, Ameniya K, Bartlett M, et al. Lyme borreliosis in rhesus macaques: Effects of corticosteroids on spirochetal load and isotype switching of anti-Borrelia burgdorferi antibody. Clin Diagn Lab Immunol 2001; 8:225-232.
14. Patel IH, Kaplan SA. Pharmacokinetic profile of ceftriaxone in man. Am J Med 1984; 77:17-25.
15. Pelak BA, Gilfillan EC, Weissberger B, et al. Quaternary heterocyclylamino beta-Lactams. vI. In vitro and in vivo antibacterial properties of L-642,946 and L-652,813, a long acting cephem. J Antibiotics 1987; 40:354-362.
16. Philipp MT, Lobet Y, Bohm RP Jr, et al. The outer surface protein A (OspA) vaccine against Lyme disease: Efficacy in the rhesus monkey. vaccine 1997; 15:1872-1887.
17. Reiman S, Grattepanche F, Rezzonico E, et al. Development of a real-Time RT-PCR method for enumeration of viable Bifidbacterium longum. Food Microbiol 2010; 27:236-242
18. Sheridan GE, Szabo EA, Macket BM. Effect of post-Treatment holding conditions on detection of tufA mRNA in ethanoltreated Escherichia coli: Implications for RT-PCR-Based indirect viability tests. Lett. Appl. Microbiol. 1999; 29:375-379.
19. Sundelof JG, Hajdu R, Gill CJ, et al. Pharmacokinetics of L- 749,345, a long-Acting carbapenem antibiotic, in primates. Antimicrob Agents Chemother 1997; 41:1743-1748.
20. Sung KD, Stern NJ, Hiett KL. Relationship of messenger RNA reverse transcriptase-Polymerase chain reaction signal to Campylobacter spp. Avian Dis 2004; 48:254-262.
21. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: Clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089-1134.
22. Wormser GP, Schwartz I. Antibiotic treatment of animals infected with Borrelia burgdorferi. Clin Microbiol Rev 2009; 22:387-395.